University of British Columbia
Vancouver, British Columbia
Optimization of autologous immune therapy using MRD expansion
The presence blood cancer cells in children completing the first phase of treatment is a strong indicator that the disease may return later. The low numbers of the cells at this stage, however, have made it difficult to evaluate their sensitivity to other treatments. Here, we will develop a new approach to increase the number of cancer cells and use these cells to develop better approaches to limit their growth and survival.